Home MarketAlkem Laboratories Ltd.

Alkem Laboratories Ltd. Stock Info: As on 2017-11-24 15:55:32

Nse

1987.90

13.45(0.68%)
Change%
52 Week Range
1,519.00
27.00
2,400.00
20.00
Open1,969.50
Day's Range1,579.56 - 2,369.34
Value Traded (in ₹ Cr.) 1.70

Bse

1978.15

1.35(0.07%)
Change %
52 Week Range
1,535.00
27.00
2,238.00
5.00
Open1,958.80
Day's Range1,581.44 - 2,372.16
Value Traded (in ₹ Cr.) 0.16

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 80,130,614.00 67.02%
Mutual Funds/UTI 2,423,566.00 2.03%
FII 4,922,684.00 4.12%
Employee 0.00 0.00%
Public 29,755,018.00 24.89%
Government 0.00 0.00%
Others 2,031,234.00 1.70%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 4.16
Basic EPS (Rs.) 53.40
Cash EPS 59.55
BVPerShare Excl 297.51
Operating Revenue 328.29
PBDITPerShare 73.01
Dividend 12.70
NPPerShare 53.40
Current Ratio 1.74
Quick Ratio 1.23
PriceToBV 4.59
Earnings 0.03
PBDIT Margin 22.23
PBT Margin 19.00
NP Margin 16.26
Return On Assets 13.15
Retention Ratios 76.21
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 4,085.21
Total Expenses 3,339.25
EBITDA 872.79
PBT 745.96
PAT 638.44
Net Income 638.44
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,932.73
Total Expenses 1,580.55
EBITDA 316.31
PBT 332.13
PAT 227.59
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 23.91
Net worth 3,556.70
Investments 1,071.13
Total Liability 4,853.33
Total debt 350.62
Net block 1,021.24
Total Assets 4,853.33
Parameter Sep-16 (₹ Cr.) 6M % change
Total share capital 23.91
Net worth 3,472.04
Investments 1,063.05
Total Liability 5,118.18
Total debt 872.21
Net block 987.26
Total Assets 5,118.18
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

535.05 535.15 -0.02
525.05537.3

Abbott India Ltd.

4977.5 4858.7 2.45
4810.055049

Ajanta Pharma Ltd.

1329.2 1327.15 0.15
1281.151362.3

Albert David Ltd.

361.2 323.55 11.64
286.1374

Alembic Ltd.

39.35 39.25 0.25
3940.2

Alembic Pharmaceuticals Ltd.

515.5 514.3 0.23
507.4520.4

Alpa Laboratories Ltd.

32.35 32.3 0.15
3133.5
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

56.5 53.35 5.9
44.0558.4

Aarti Drugs Ltd.

532.1 532 0.02
513.4537

Aayush Food & Herbs Ltd.

47.7 47.9 -0.42
45.0552.7

Abbott India Ltd.

4968.65 4861.15 2.21
4825.655085

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 629.81
Cash from investing activities 310.84
Cash from financing activities -958.16
Net change in cash -17.48

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Motilal Oswal MOSt Focused Multicap 35 Fund 2.24%
DSP BlackRock Small And Mid Cap Fund 1.61%
Reliance Growth Fund 1.02%
SBI Pharma Fund 4.44%
UTI Growth Sector Fund - Pharma and Healthcare 4.29%
Axis Emerging Opportunities Fund - Series 1 2.45%

Excel Industries Q2 net profit jumps 60.26% at Rs 11.01 cr

The company reported standalone net profit of Rs 11.01 crore for the quarter ended September 30, 2017 as compared to Rs 6.87 crore in the same period last year, registering a year-on-year growth of 60.26 per cent. Net revenue of the company rose moderately by 6.02 per cent at Rs 130.02 crore in July-September quarter of this fiscal as against Rs 122.64 crore in the corresponding period last year. During July-September quarter, operating expenses dropped by 0.72 per cent to Rs 108.27 crore from Rs 109.05 crore in year ago period. Other Income dipped by 71.76 per cent at Rs 0.24 crore versus (Sep'16 Rs 0.85 crore). Operating Profit surged by 45.68 per cent to Rs 21.75 crore as against Rs 14.93 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 37.36 per cent in September quarter. Interest declined by 47.90 per cent y-o-y to Rs 1.61 crore, while Taxation increased by 156.31 per cent at Rs 5.69 crore (Sep'16 Rs 2.22 crore).

24-11-2017 16:50

Skyline Millars posts Q2 net loss of Rs 0.16 cr

The company reported standalone net loss during the quarter stood at Rs 0.16 crore compared to net profit of Rs 0.53 crore in the previous year quarter. Net revenue of the company rose two fold by 245.45 per cent at Rs 1.14 crore in July-September quarter of this fiscal as against Rs 0.33 crore in the corresponding period last year. During July-September quarter, operating expenses increased by 7.37 per cent to Rs 1.02 crore from Rs 0.95 crore in year ago period. Other Income dipped by 99.43 per cent at Rs 0.01 crore versus (Sep'16 Rs 1.74 crore). Operating Profit surged by 119.35 per cent to Rs 0.12 crore as against Rs -0.62 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 105.56 per cent in September quarter.

24-11-2017 16:40

Kingfa Science & Technology Q2 net profit up 21.77%

The company reported standalone net profit of Rs 5.09 crore for the quarter ended September 30, 2017 as compared to Rs 4.18 crore in the same period last year, registering a year-on-year growth of 21.77 per cent. Net revenue of the company rose substantially by 24.78 per cent at Rs 139.87 crore in July-September quarter of this fiscal as against Rs 112.09 crore in the corresponding period last year. During July-September quarter, operating expenses increased by 23.44 per cent to Rs 130.01 crore from Rs 105.32 crore in year ago period. Other Income grew by 1058.33 per cent at Rs 1.15 crore versus (Sep'16 Rs -0.12 crore). Operating Profit surged by 45.86 per cent to Rs 9.86 crore as against Rs 6.76 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 16.92 per cent in September quarter. Interest grew by 257.75 per cent y-o-y to Rs 1.12 crore, while Taxation increased by 68.61 per cent at Rs 3.76 crore (Sep'16 Rs 2.23 crore).

24-11-2017 16:30

Valiant wins orders worth Rs 5 cr for metro projects

Valiant Communications on Friday said it has received the product approvals and letter of intents for supply of its communication solutions for Kolkata Metro Rail Corporation and Dedicated Freight Corridor projects for western Region. “The gross value of the projects exceeds Rs 5 crore,” Valiant Communications said in a filing to the Bombay Stock Exchange. Commenting on the development, Inder Mohan Sood, Managing Director said: “These are significant developments, as it also opens up the railway sector for the company to participate in the upgradation of Indian Railways.” Meanwhile, shares of company closed trade at Rs 84.00 apiece, up 6.94 per cent, on the BSE today.

24-11-2017 16:16

Alexander Stamps Q2 net profit up 6.25% at Rs 0.17 cr

The company reported standalone net profit of Rs 0.17 crore for the quarter ended September 30, 2017 as compared to Rs 0.16 crore in the same period last year, registering a year-on-year growth of 6.25 per cent. Net revenue of the company declined substantially by 57.74 per cent at Rs 1.31 crore in July-September quarter of this fiscal as against Rs 3.10 crore in the corresponding period last year. During July-September quarter, operating expenses dropped by 62.76 per cent to Rs 1.08 crore from Rs 2.90 crore in year ago period. Operating Profit surged by 15.00 per cent to Rs 0.23 crore as against Rs 0.20 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 169.71 per cent in September quarter. Taxation increased by 40.00 per cent at Rs 0.07 crore (Sep'16 Rs 0.05 crore).

24-11-2017 15:10

Alkem Laboratories Q2 net profit up 12.07% at Rs 330.76 cr

The company reported standalone net profit of Rs 330.76 crore for the quarter ended September 30, 2017 as compared to Rs 295.14 crore in the same period last year, registering a year-on-yeargrowthof 12.07 per cent. Net revenue of the company rose substantially by 20.09 per cent at Rs 1,568.02 crore in July-September quarter of this fiscal as against Rs 1,305.68 crore in the corresponding period last year. During July-September quarter, operating expenses increased by 9.64 per cent to Rs 1,125.56 crore from Rs 1,026.64 crore in year ago period. Other Income dipped by 33.85 per cent at Rs 20.30 crore versus (Sep'16 Rs 30.69 crore). Operating Profit surged by 47.20 per cent to Rs 442.46 crore as against Rs 300.58 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 22.59 per cent in September quarter. Interest grew by 63.06 per cent y-o-y to Rs 11.30 crore, while Taxation increased by 857.16 per cent at Rs 94.95 crore (Sep'16 Rs 9.92 crore).

10-Nov-2017 02:36 PM

Alkem Laboratories - Trading Window

Alkem Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

10-Nov-2017 02:02 PM

Alkem Laboratories - Updates

We refer to our earlier communication dated 28th September, 2017 regarding closure of trading window (for the purpose of financial results for the quarter and half year ended 30th September, 2017) starting from 29th September, 2017 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and half year ended on 30th September, 2017 are communicated to the Stock Exchanges.

The Financial Results of the Company for the quarter and half year ended 30th September, 2017 having been communicated to the Stock Exchanges, today i.e. 10th November, 2017, the trading window shall open on 13th November, 2017.

10-Nov-2017 02:01 PM

Alkem Laboratories - Press Release / Media Release

With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith press release and analyst presentation on Q2FY18 and H1FY18 earnings and business updates and the same will be uploaded on the website of the Company.

Kindly take note of the same.

10-Nov-2017 01:51 PM

Alkem Laboratories - Investor Presentation

Alkem Laboratories Limited has informed the Exchange regarding Investor Presentation

10-Nov-2017 01:50 PM

Alkem Laboratories - Updates

We refer to our earlier communication dated 28th September, 2017 regarding closure of trading window (for the purpose of financial results for the quarter and half year ended 30th September, 2017) starting from 29th September, 2017 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and half year ended on 30th September, 2017 are communicated to the Stock Exchanges.

The Financial Results of the Company for the quarter and half year ended 30th September, 2017 having been communicated to the Stock Exchanges, today i.e. 10th November, 2017, the trading window shall open on 13th November, 2017.

10-Nov-2017 02:01 PM

Alkem Laboratories - Press Release / Media Release

With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith press release and analyst presentation on Q2FY18 and H1FY18 earnings and business updates and the same will be uploaded on the website of the Company.

Kindly take note of the same.

10-Nov-2017 01:51 PM

Alkem Laboratories - Financial Results For Quarter And Half Year Ended 30Th September, 2017

In continuation of our letter dated 1st November, 2017 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we are enclosing the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2017, duly approved by the Board of Directors of the Company, at its meeting held today, i.e. 10th November, 2017. The meeting of the Board of Directors of the Company commenced at 10.30 a.m. and concluded at 1.30 p.m.

A copy of the Standalone and Consolidated Unaudited Financial Results, Limited Review Report of the Statutory Auditors of the Company, Press Release ad Investor Presentation are enclosed herewith.

Kindly take the same on record.

10-Nov-2017 01:49 PM

Corporate Details

About Management

The Company was incorporated as a private limited company `Alkem Laboratories Private Limited' on August 8,1973 at Patna under the Companies Act, 1956 and subsequently became a deemed public limited company under section 43A(2) of Companies Act, 1956 on October 26, 1988. Pursuant to the Company passing a resolution under section 21 of Companies Act, 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21, 2001, the name of the Company was changed to `Alkem Laboratories Limited' with effect from October 26, 1988. the registered office was originally located at `Exhibition Road, Patna - 800 001, Bihar, India'. the Company filed Company Petition No. 356(17)/ ERB/ 2007 before the Company Law Board, Eastern Region Bench at Kolkata for shifting the registered office of the Company from the State of Bihar to the State of Maharashtra, as approved by a special resolution at its extra-ordinary general meeting held on January 29, 2007. The Company Law Board, Eastern Region Bench at Kolkata passed an order dated July 30, 2007 whereby it confirmed the alteration of the situation clause in the Memorandum of Association, from the State of Bihar to the State of Maharashtra. Pursuant to the order, the registered office of the Company was shifted to `Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013, Maharashtra, India' with effect from August 2, 2007. Major Events : 1973 -Incorporation of the Company. 1978 -the Company established its first plant at Taloja, Maharashtra. 1988 -the Company became a deemed public limited company. 1992 -the Company established its manufacturing facility in Mandwa, Maharashtra. This facility was converted into an API facility in 2005. 1998 -the Company established its Kachigam manufacturing facility in Gujarat. 2001 -Startronic Pharmachem Private Limited and Indo Propkem amalgamated with the Company. 2002 -the Company established its Amaliya manufacturing facility in Gujarat. 2003 -the Company set up its research and development facility at Taloja, Maharashtra. 2005 -the Company established its manufacturing facility in Baddi, Himachal Pradesh. 2006 -the anti-infective drug Taxim became the first drug in the Indian pharmaceutical industry to cross 1,000 million in terms of domestic sales in India (Source: IMS Research) 2007 -the Company established its manufacturing facility in Kumrek, Sikkim. -the Company filed its first ANDA in the United States for the drug, Amlodipine. -the Company shifted its Registered Office from Patna, Bihar to Mumbai, Maharashtra. 2009 -the Company acquired Pharmacor, a generic pharma company in Australia. 2010 -the Company acquired The PharmaNetwork, LLC, the holding company of Ascend Laboratories LLC. 2011 -the Company acquired Enzene Bio sciences Limited. 2012 -the Company acquired an API manufacturing facility in the United States. 2014 -the Company acquired the Clindac. 2015 -the Company acquired a formulation manufacturing facility in the United States. Awards and achievements: 2002 -the Company was awarded the Pharma Business and Technology Excellence Award in 2002 as 'India's Most Esteemed Pharmaceutical Company' 2004 -the product Taxim was awarded the Pharma Business and Technology Excellence Award for successful brand in 2004 2005 -the Company was awarded the Overall Performance Award for Group B at the 5th Express Pharma Awards in 2005 2009 -the Company received a certificate of appreciation for outstanding export performance in the category of formulations by the Pharmaceuticals Export Promotion Council of India, supported by Ministry of Commerce and Industry, GOI -the Company received the certificate of appreciation in the category of `Formulation Experts' by the Pharmaceuticals Export Promotion Council of India, supported by Ministry of Commerce and Industry, GOI 2013 -the Company was awarded the India's most admired pharma company award for 2013 at the 6th Annual Pharmaceutical Leadership Summit in 2013 2014 -the Product `Clavam' was awarded as the ` Brand of the Year' at the AWACS Award, 2014 2016 -Alkem's Mandva Plant successfully obtains the Establishment Inspection Report from the US FDA -Alkem receives EIR from the US FDA for its Daman formulation facility

Registered Office

MIDC, Taloja

,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.